Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pre-exposure Prophylaxis of SARS-CoV-2 Infection (COVID-19) by Monoclonal Antibodies With Early Access Authorization in Immunocompromised Patients. A Prospective Cohort.

NCT05216588 is registered in ClinicalTrials.gov with ANRS, Emerging Infectious Diseases as lead sponsor.

NCT NCT05216588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05216588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pre-exposure Prophylaxis of SARS-CoV-2 Infection (COVID-19) by Monoclonal Antibodies With Early Access Authorization in Immunocompromised Patients. A Prospective Cohort.
Lead sponsor
ANRS, Emerging Infectious Diseases
Phase
Observational
Overall status
Completed
Start date
January 26, 2022
Completion date
October 31, 2024
Enrollment
149 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, immunocompromised host